3.68
+0.12(+3.37%)
Currency In USD
| Previous Close | 3.56 |
| Open | 3.63 |
| Day High | 3.71 |
| Day Low | 3.5 |
| 52-Week High | 14.25 |
| 52-Week Low | 2.86 |
| Volume | 1.55M |
| Average Volume | 2.65M |
| Market Cap | 328.8M |
| PE | -6.81 |
| EPS | -0.54 |
| Moving Average 50 Days | 5.13 |
| Moving Average 200 Days | 8.29 |
| Change | 0.12 |
If you invested $1000 in Anavex Life Sciences Corp. (AVXL) 10 years ago, it would be worth $601.31 as of January 05, 2026 at a share price of $3.68. Whereas If you bought $1000 worth of Anavex Life Sciences Corp. (AVXL) shares 5 years ago, it would be worth $711.8 as of January 05, 2026 at a share price of $3.68.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion
GlobeNewswire Inc.
Dec 18, 2025 12:30 PM GMT
NEW YORK, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
GlobeNewswire Inc.
Dec 12, 2025 9:05 PM GMT
NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease,
Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
GlobeNewswire Inc.
Nov 26, 2025 12:30 PM GMT
One Oral Late Breaking Communication and Two Poster PresentationsNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing inn